The 'Orphan' Label Has Outgrown Its Job

The word "orphan" in US drug law was meant to describe a market failure: a medicine for so few patients that no ordinary return on R&D would draw a manufacturer in. Once the statute extends that label to drugs earning blockbuster revenue, the protection stops rewarding invention. It rewards a definition.

That is the mechanism a STAT+ Pharmalot analysis names in finding that the One Big Beautiful Bill Act's orphan-drug provision "may not warrant that protection." Under the original Inflation Reduction Act, an orphan drug was exempt from Medicare price negotiations only when it had a single rare-disease approval. The new provision broadens that exemption to multi-designation orphans and delays negotiation timelines for otherwise-eligible ones. Health Affairs Forefront has separately called this the blockbuster orphan paradox: high-revenue rare-disease drugs receiving the same shield as the genuine single-indication cases the law was built to coax into being.

The mechanism is portable. A category designed to fill an investment gap gets widened to whatever the statute can technically cover, until the original rationale becomes rhetorical cover for whatever carve-out drafters want. KFF's projection of higher Medicare beneficiary cost-sharing is the price rare-disease patients pay for a definition that no longer tracks its stated mission. Right-sizing means tying the exemption to a market-size or revenue test, not a designation count. Until then, "orphan" is a label the statute can wear without earning.